

On the ABSTRACT page, please delete the paragraph at lines 19-22 and insert the following paragraph:

Abstract

89
LL
C1
✓- SA The invention relates to C₂₋₂₀alkanoic acid esters of 3-
[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-
6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]-
pyrimidin-4-one, pharmaceutically acceptable acid addition
salts thereof, and enantiomeric forms thereof, which are useful
in the treatment of warm-blooded animals suffering from
psychotic diseases. EA ✓-

REMARKS

Reconsideration of this application in its amended form
is respectfully requested.

N
P
N
K
In the specification, the status of the parent application has
been brought up to date and the ABSTRACT has been amended as
suggested by the Examiner.

Enclosed herewith is a TERMINAL DISCLAIMER whereby the Assignee
of the entire right, title and interest in the subject application
disclaims the terminal part of any patent granted on this applica-
tion which would extend beyond the expiration date of U.S. Patent
No. 5,158,952.

It is respectfully submitted that the present amendments to the specification and the submission of the said TERMINAL DISCLAIMER places this application in condition for allowance. Early favorable action is respectfully requested.

Respectfully submitted,



Charles J. Metz
Attorney for Applicants
Registration #20,359

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933

(908) 524-2814

December 30, 1992